249 related articles for article (PubMed ID: 31550725)
41. Prognostic significance of PD-L2 expression in patients with oral squamous cell carcinoma-A comparison to the PD-L1 expression profile.
Weber M; Wehrhan F; Baran C; Agaimy A; Büttner-Herold M; Kesting M; Ries J
Cancer Med; 2019 Mar; 8(3):1124-1134. PubMed ID: 30659749
[TBL] [Abstract][Full Text] [Related]
42. PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients.
Kim HR; Ha SJ; Hong MH; Heo SJ; Koh YW; Choi EC; Kim EK; Pyo KH; Jung I; Seo D; Choi J; Cho BC; Yoon SO
Sci Rep; 2016 Nov; 6():36956. PubMed ID: 27841362
[TBL] [Abstract][Full Text] [Related]
43. The immune microenvironment of HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma: a multiparametric quantitative and spatial analysis unveils a rationale to target treatment-naïve tumors with immune checkpoint inhibitors.
Tosi A; Parisatto B; Menegaldo A; Spinato G; Guido M; Del Mistro A; Bussani R; Zanconati F; Tofanelli M; Tirelli G; Boscolo-Rizzo P; Rosato A
J Exp Clin Cancer Res; 2022 Sep; 41(1):279. PubMed ID: 36123711
[TBL] [Abstract][Full Text] [Related]
44. Programmed cell death protein 1/programmed death ligand 1 but not HER2 is a potential therapeutic target in gastric neuroendocrine carcinoma.
Yamashita S; Abe H; Kunita A; Yamashita H; Seto Y; Ushiku T
Histopathology; 2021 Feb; 78(3):381-391. PubMed ID: 32767778
[TBL] [Abstract][Full Text] [Related]
45. Frequency and prognostic significance of p16(INK4A) protein overexpression and transcriptionally active human papillomavirus infection in laryngeal squamous cell carcinoma.
Young RJ; Urban D; Angel C; Corry J; Lyons B; Vallance N; Kleid S; Iseli TA; Solomon B; Rischin D
Br J Cancer; 2015 Mar; 112(6):1098-104. PubMed ID: 25688737
[TBL] [Abstract][Full Text] [Related]
46. HPV-associated neuroendocrine carcinoma of the oropharynx: a rare new entity with potentially aggressive clinical behavior.
Kraft S; Faquin WC; Krane JF
Am J Surg Pathol; 2012 Mar; 36(3):321-30. PubMed ID: 22301491
[TBL] [Abstract][Full Text] [Related]
47. Prognostic value of programed death ligand-1 and ligand-2 co-expression in salivary gland carcinomas.
Nakano T; Takizawa K; Uezato A; Taguchi K; Toh S; Masuda M
Oral Oncol; 2019 Mar; 90():30-37. PubMed ID: 30846173
[TBL] [Abstract][Full Text] [Related]
48. Turning the tide: Clinical utility of PD-L1 expression in squamous cell carcinoma of the head and neck.
De Meulenaere A; Vermassen T; Aspeslagh S; Huvenne W; Van Dorpe J; Ferdinande L; Rottey S
Oral Oncol; 2017 Jul; 70():34-42. PubMed ID: 28622889
[TBL] [Abstract][Full Text] [Related]
49. Impact of PD-L1 expression and human papillomavirus status in anti-PD1/PDL1 immunotherapy for head and neck squamous cell carcinoma-Systematic review and meta-analysis.
Patel JJ; Levy DA; Nguyen SA; Knochelmann HM; Day TA
Head Neck; 2020 Apr; 42(4):774-786. PubMed ID: 31762164
[TBL] [Abstract][Full Text] [Related]
50. RNA in-situ hybridization is a practical and effective method for determining HPV status of oropharyngeal squamous cell carcinoma including discordant cases that are p16 positive by immunohistochemistry but HPV negative by DNA in-situ hybridization.
Rooper LM; Gandhi M; Bishop JA; Westra WH
Oral Oncol; 2016 Apr; 55():11-6. PubMed ID: 27016012
[TBL] [Abstract][Full Text] [Related]
51. Clinicopathological and Prognostic Analysis of PD-L1 and PD-L2 Expression in Surgically Resected Primary Tongue Squamous Cell Carcinoma.
Furukawa K; Kawasaki G; Yoshida T; Umeda M
Anticancer Res; 2021 Jan; 41(1):101-111. PubMed ID: 33419803
[TBL] [Abstract][Full Text] [Related]
52. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
[TBL] [Abstract][Full Text] [Related]
53. PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer.
Yearley JH; Gibson C; Yu N; Moon C; Murphy E; Juco J; Lunceford J; Cheng J; Chow LQM; Seiwert TY; Handa M; Tomassini JE; McClanahan T
Clin Cancer Res; 2017 Jun; 23(12):3158-3167. PubMed ID: 28619999
[No Abstract] [Full Text] [Related]
54. Expression of PD-L1 on Immune Cells Shows Better Prognosis in Laryngeal, Oropharygeal, and Hypopharyngeal Cancer.
Birtalan E; Danos K; Gurbi B; Brauswetter D; Halasz J; Kalocsane Piurko V; Acs B; Antal B; Mihalyi R; Pato A; Fent Z; Polony G; Timar J; Tamas L
Appl Immunohistochem Mol Morphol; 2018 Aug; 26(7):e79-e85. PubMed ID: 29271789
[TBL] [Abstract][Full Text] [Related]
55. M1 macrophages induce PD-L1
Wu J; Pang X; Yang X; Zhang M; Chen B; Fan H; Wang H; Yu X; Tang Y; Liang X
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38148114
[TBL] [Abstract][Full Text] [Related]
56. Evaluation of programmed cell death ligand 1 expression in a contemporary cohort of penile squamous cell carcinoma and its correlation with clinicopathologic and survival parameters: A study of 134 patients.
Lobo A; Mishra SK; Jha S; Tiwari A; Kapoor R; Sharma S; Kaushal S; Kiranmai NS; Das MR; Peddinti KP; Sharma SK; Bhardwaj N; Arora S; Jain D; Jain E; Munjal G; Shinde S; Malik V; Singh H; Varshney J; Pradhan D; Dixit M; Pattnaik N; Sharma AK; Barapatre YR; Pradhan M; Satapathy K; Rath D; Jaiswal S; Das S; Khadenga C; Routa S; Baisakh MR; Tiwari R; Sampat NY; Chakrabarti I; Parwani AV; Mohanty SK
Am J Clin Pathol; 2024 Jan; 161(1):49-59. PubMed ID: 37639681
[TBL] [Abstract][Full Text] [Related]
57. P16(INK4A) immunostaining is a strong indicator for high-risk-HPV-associated oropharyngeal carcinomas and dysplasias, but is unreliable to predict low-risk-HPV-infection in head and neck papillomas and laryngeal dysplasias.
Mooren JJ; Gültekin SE; Straetmans JM; Haesevoets A; Peutz-Kootstra CJ; Huebbers CU; Dienes HP; Wieland U; Ramaekers FC; Kremer B; Speel EJ; Klussmann JP
Int J Cancer; 2014 May; 134(9):2108-17. PubMed ID: 24127203
[TBL] [Abstract][Full Text] [Related]
58. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas.
Yang MW; Fu XL; Jiang YS; Chen XJ; Tao LY; Yang JY; Huo YM; Liu W; Zhang JF; Liu PF; Liu Q; Hua R; Zhang ZG; Sun YW; Liu DJ
World J Gastroenterol; 2019 Apr; 25(14):1684-1696. PubMed ID: 31011254
[TBL] [Abstract][Full Text] [Related]
59. A proportion of primary squamous cell carcinomas of the parotid gland harbour high-risk human papillomavirus.
Xu B; Wang L; Borsu L; Ghossein R; Katabi N; Ganly I; Dogan S
Histopathology; 2016 Dec; 69(6):921-929. PubMed ID: 27374168
[TBL] [Abstract][Full Text] [Related]
60. Expression profile and in vitro blockade of programmed death-1 in human papillomavirus-negative head and neck squamous cell carcinoma.
Malm IJ; Bruno TC; Fu J; Zeng Q; Taube JM; Westra W; Pardoll D; Drake CG; Kim YJ
Head Neck; 2015 Aug; 37(8):1088-95. PubMed ID: 24710745
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
